Medifast Stock Rating Lowered by Zacks (MED)
Medifast (NYSE:MED) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report issued on Tuesday. They currently have a $25.50 price objective on the stock. Zacks‘s price target would indicate a potential downside of 5.13% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Canaccord Genuity cut their price target on shares of Medifast from $32.00 to $29.00 in a research note on Friday. Separately, analysts at Wedbush cut their price target on shares of Medifast from $37.00 to $32.00 in a research note on Friday. Finally, analysts at Imperial Capital cut their price target on shares of Medifast from $36.00 to $34.00 in a research note on Friday. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company’s stock. Medifast has an average rating of “Hold” and an average target price of $29.10.
Medifast (NYSE:MED) traded down 1.92% during mid-day trading on Tuesday, hitting $26.365. 122,078 shares of the company’s stock traded hands. Medifast has a one year low of $23.02 and a one year high of $34.40. The stock has a 50-day moving average of $29.77 and a 200-day moving average of $29.45. The company has a market cap of $335.3 million and a price-to-earnings ratio of 15.93.
Medifast (NYSE:MED) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.44 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.39 by $0.05. The company had revenue of $80.88 million for the quarter, compared to the consensus estimate of $87.30 million. During the same quarter in the prior year, the company posted $0.51 earnings per share. The company’s quarterly revenue was down 16.7% on a year-over-year basis. Analysts expect that Medifast will post $1.75 EPS for the current fiscal year.
Medifast, Inc (NYSE:MED) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.